Author: Mehak Srivastava

Ras Al Khaimah based Julphar Gulf Pharmaceutical Industries (Julphar), the largest generic pharmaceutical manufacturer in Middle East and North Africa (MENA), announced sales revenue of AED639mn ($173.97mn) in the first semester of this year. The company also revealed a net profit of AED64mn ($17.42mn) for the same period. Sheikh Faisal Bin Saqr Al Qasimi, chairman at Julphar, said: “We are very proud of the success we have achieved since the beginning of the year. Dandasha has been launched during Q1 in the UAE to treat erectile dysfunction in adult men and by Q2, it has become a leader in its segment.”…

Read More